Cannabis Europa returned to Paris on February 19, 2026. This event marked a significant moment for France’s developing medical cannabis industry. French authorities presented a preliminary draft of the medical cannabis reimbursement framework. This is a crucial regulatory step. It allows France to move from a pilot program to a permanent market. Industry stakeholders received firsthand accounts of the discussions. Stephen Murphy, Co-Founder and CEO of Prohibition Partners, noted the market’s evolution. He highlighted progress since 2019. This development is major news for the trending cannabis sector.
France’s Transition to a Permanent Market
France is officially ending its five-year medical cannabis pilot program. The pilot concludes on March 31, 2026. A permanent, pharmaceutical-style regime begins April 1, 2026. This new framework will define access and pricing. It will also guide supply and prescriber rights for the next decade. The pilot enrolled 3,209 patients. However, only 1,849 remained in active treatment. The permanent regime aims to widen patient access. It seeks to create a more robust national system. This shift is more consequential than many European reforms.
The Draft Reimbursement Framework Details
The draft framework introduces a tiered reimbursement structure. The Haute Autorité de Santé (HAS) will assess each product’s benefit. Coverage rates could be 65%, 30%, 10%, or 0%. This depends on the assessed medical value. Patients with long-term conditions (ALD status) will likely see 100% coverage. This is a key factor for patient lifestyle improvements. Pricing will use homogeneous product categories. Prices will be fixed for three years. They may be revised based on new clinical evidence. The Direction Générale de la Santé (DGS) and Direction de la Sécurité Sociale (DSS) organized the consultation.
Key Timelines and Next Steps
Regulatory decrees concerning cultivation and technical specifications are expected soon. Formal adoption is anticipated for June 2026. Companies can then begin product registration with the ANSM. HAS will resume its evaluations concurrently. A final HAS opinion on reimbursement is expected between October and November 2026. Patients in the pilot program will be covered until December 31, 2026.
Implications for Patients and the Industry
The new framework promises greater patient access. However, challenges remain. Prescriber training is a significant bottleneck. Currently, only a limited number of healthcare professionals are certified. The goal is a sovereign “Made in France” supply chain. However, domestic cultivation capacity is still developing. This creates a reliance on imports for two to three years. International suppliers will be essential during this period. The French market could grow significantly. Prohibition Partners projects it could reach €806 million by 2035. This growth hinges on robust reimbursement structures. It also depends on broad patient access.
A New Era for Medical Cannabis
France’s move signifies a major regulatory milestone. It transitions from a cautious pilot to a permanent, pharmaceutical-style regime. The event at Cannabis Europa Paris provided critical insights. It highlighted the country’s structured approach. This includes stringent clinical and technical demands. The new framework aims to reduce stigma. It seeks to improve patient access to cannabis medicines. This marks a significant advancement for the European cannabis news landscape. The industry anticipates further details on pricing viability. This crucial step could unlock the market’s full potential. It offers a durable and potentially exportable model for other nations. This development offers promising lifestyle benefits for many patients.
